613. Acute Myeloid Leukemia: Clinical and Epidemiological: COVID and beyond


Akriti G Jain, Ning C. Dong, Somedeb Ball, et al. 

The vast majority of patients with AML and MDS were seropositive after two doses of the vaccine. Most clinical and laboratory variables did not affect the seropositivity rate. The antibody titer values rose sharply after the 2nd vaccination dose. This indicates the benefit of serial vaccination (i.e. additional dosing) in poorly responding patients. The mRNA-273 SARS-CoV-2 vaccine induces a strong humoral response in this study group of AML- and MDS-patients.



Jil Rotterdam, Margot Thiaucourt, Juliana Schwaab, et al. 

In patients with low-grade NHL, MDS and autoimmune diseases, no or only a weak immune response was measured after the 2nd COVID vaccination. Patients with MPN seem to respond slightly better, and CML patients have no problems.


219 ASH denotes this abstract as clinically relevant 

Isla M. Johnson, Evandro D. Bezerra, Faiqa Farrukh, et al. 

In AML patients taking Venetoclax + HMA, cardiac complications occurred in 20 percent, although around 30 percent of these patients had no pre-existing heart disease; the mortality was 27 percent.



Xu Wang, Ian Thomas, Cono Ariti, et al. 

The consideration of cytogenetic risk, FLT3-ITD and NPM1 mutation status only improved the prognostic accuracy minimally. This also applies to some of the QLQ-C30 subscales. The study results indicate the difficulty of predicting outcomes of non-intensive AML therapy with routinely available clinical baseline data.



Karilyn Larkin, Deedra Nicolet, Ben Kelly, et al. 

Black AYA-AML patients have distinct molecular features (including high frequencies of CBF-AML and low frequencies of NPM1). The age group between 18 and 29 years of age is primarily responsible for the race-related disparity in survival, especially those without CBF with very poor survival. The lower CR rates combined with persistent dominant clones at relapse indicate a reduced response to induction chemotherapy. This indicates different treatment intensities and / or modalities required in these patients. High rates of premature death indicate delays in diagnosis and care. This means that systematic health inequalities, especially in this population group, must be changed.



Gi June Min, Byung Sik Cho, Sung-Soo Park, et al. 

The prognostic value of the physical and psychological assessment by GA for the survival results in intensively treated eAML patients could be proven with this study. Non-fatal toxicities during intensive chemotherapy in eAML patients could be identified based on cognitive and physical impairments. These study results will facilitate the integration of GA measures into validated survival prediction models. This will lead the way in determining the initial treatment of eAML patients in routine clinical care and clinical trials.